ANZ share price drops as Aussie banks slide; what to watch before Wednesday’s ASX open
20 January 2026
2 mins read

ANZ share price drops as Aussie banks slide; what to watch before Wednesday’s ASX open

SYDNEY, Jan 20, 2026, 17:40 (AEDT) — Market closed

  • ANZ slipped 1.15% to finish at A$36.94, dragging the financial sector down.
  • Traders are shifting their attention back to Australian jobs and inflation figures, which could recalibrate expectations around interest rates
  • Upcoming catalysts include the Jan 22 labour force data, Jan 28 CPI figures, and the RBA’s decision on Feb 3

ANZ Group Holdings shares dipped 1.15%, closing at A$36.94 on Tuesday. The decline followed a wider sell-off in Australian bank stocks, with investors reducing their financials holdings toward the session’s end. The stock fluctuated between A$36.81 and A$37.33. (Google)

This move is crucial since big banks are at the heart of the interest-rate narrative. Even minor changes in expectations for the Reserve Bank of Australia’s cash rate — the key policy rate — can quickly impact funding costs, loan demand, and concerns over bad debt.

Australia’s share market dropped again, with the S&P/ASX 200 slipping 0.66% to 8,815.9 points. Trade tensions dampened sentiment, hitting BHP particularly hard. The Australian dollar edged up, trading around 67.37 U.S. cents. (ABC)

All four major lenders took a hit. Commonwealth Bank slid 1.81%, Westpac dropped 0.98%, National Australia Bank lost 0.85%, and ANZ also declined. (News)

“The sector is cooling off as investors pull back,” Philip Pepe, senior equities analyst at Shaw and Partners, said in a note reported by The Business Times. He highlighted a reversal in rate expectations that erased earlier gains tied to anticipated cuts. (The Business Times)

Offshore jitters spilled over into Asia. Henry Cook, MUFG’s Europe economist, warned that “tariff uncertainty will remain elevated” even if tensions ease, as markets absorbed a new round of trade-war chatter. (Reuters)

For ANZ and its rivals, this balance is tricky. While higher rates can boost net interest margin—the gap between loan earnings and deposit costs—stricter policies risk squeezing borrowers and dragging down credit growth.

On the local front, all eyes turn to the labour force report set for Thursday, Jan. 22, at 11:30 a.m. (AEDT). Market watchers will focus on unemployment and participation rates to gauge if the economy is slowing or staying steady. (Australian Bureau of Statistics)

Next Wednesday, Jan. 28, at 11:30 a.m. (AEDT), the December-quarter consumer price index — the CPI — is set for release. This key inflation measure could sway rate-hike bets: a hotter figure may ramp them up, while a cooler one might dial them back. (Australian Bureau of Statistics)

The RBA’s upcoming policy meeting is set for Feb. 2–3, with the decision statement scheduled for 2:30 p.m. (AEDT) on Feb. 3, per the central bank’s calendar. (Reserve Bank of Australia)

Risks cut both ways. An unexpected slump in jobs or inflation might push rate expectations lower and stabilize bank shares. On the other hand, stronger-than-expected data or renewed trade tensions could fuel volatility and deepen the sector’s decline.

Investors will be watching closely to see if Tuesday’s bank selloff spills over into Wednesday’s open. Early moves will likely hinge on global risk appetite and bond yields, as markets brace for Thursday’s jobs report.

Stock Market Today

  • Intellia Therapeutics (NTLA) Shares Rebound Amid Conflicting Valuation Signals
    January 20, 2026, 1:57 AM EST. Intellia Therapeutics (NTLA) shares jumped 35.4% in the past month, recovering from a 53.7% decline over three months. Trading at US$12.50, the stock's recent gain contrasts with a 31.6% total loss over one year. Analysts' price targets average US$22.27, implying a 43.9% upside, based on optimistic assumptions about rapid revenue growth and expanded patient markets in gene-editing therapies. However, challenges like FDA clinical holds and competition in gene and RNA therapies cloud the outlook. Another model, the SWS discounted cash flow (DCF), values NTLA at about US$233.98, suggesting the shares might be significantly undervalued. Investors face a choice between cautious skepticism and aggressive long-term growth forecasts amid volatility and risk in biotech investment.
Silver price today: MCX silver crosses Rs 3 lakh/kg as gold hits record after Trump tariff threat
Previous Story

Silver price today: MCX silver crosses Rs 3 lakh/kg as gold hits record after Trump tariff threat

Go toTop